Insider · CIK 0002039078
Mukund Paravasthu
Files at NVCR (NovoCure Ltd). First filing Nov 4, 2024, latest Mar 5, 2026.
In brief
Mukund Paravasthu files SEC Form 4 as COO at NVCR (NovoCure Ltd). Since Nov 4, 2024, Mukund Paravasthu has reported 0 open-market buys worth $0 and 5 open-market sells worth $708k, the latest filed on Mar 5, 2026.
A track record needs three past buys with six months of prices behind them; Mukund Paravasthu has 0, so none is measured yet.
The newest scored trade: sold $667k of NVCR on Mar 4, 2026, filed Mar 5, 2026, scored 65 (notable). In the last 12 months: 0 buys worth $0 and 2 sells worth $694k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NVCR: NovoCure Ltd
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 65Notable | NovoCure Ltd | $667k 48,623 shares | -40% | +34% from low-37% from high | |
| 40Moderate | NovoCure Ltd | $27k 1,963 shares | -3% | +36% from low-36% from high | |
| 20Weak | NVCRsell NovoCure Ltd | $11k 592 shares | -1% | +25% from low-46% from high | |
| 35Weak | NovoCure Ltd | $734 44 shares | -1% | - | |
| 35Weak | NovoCure Ltd | $2,540 160 shares | -4% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 5, 2026 | NVCR NovoCure Limited | 43,246 0.04% of outstanding | $596k | Mar 5, 2026 | $129k |
| Mar 4, 2026 | NVCR NovoCure Limited | 5,377 0.00% of outstanding | $72k | Mar 4, 2026 | $27k |
| May 5, 2025 | NVCR NovoCure Limited | 592 0.00% of outstanding | $11k | May 5, 2025 | $44k |
| Mar 3, 2025 | NVCR NovoCure Limited | 250 0.00% of outstanding | $4,634 | Mar 3, 2025 | $97k |
| Feb 28, 2025 | NVCR NovoCure Limited | 368 0.00% of outstanding | $6,729 | Feb 28, 2025 | $91k |
| Feb 27, 2025 | NVCR NovoCure Limited | 1,646 0.00% of outstanding | $33k | Feb 27, 2025 | $58k |
| Jan 13, 2025 | NVCR NovoCure Limited | 2,160 0.00% of outstanding | $58k | Jan 13, 2025 | $3,276 |
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | NVCR NovoCure Ltd | AGrant or award Ordinary Shares | +45,112 | $0.00 | $0 | 121,455 | Mar 5, 2026 |
| Mar 4, 2026 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -5,377 | $13.31 | $72k | 116,078 | Mar 5, 2026 |
| Mar 5, 2026 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -43,246 | $13.77 | $596k | 72,832 | Mar 5, 2026 |
| Mar 3, 2026 | NVCR NovoCure Ltd | AGrant or award Stock Option (Right to Buy)derivative | +7,518 | $0.00 | $0 | 7,518 | Mar 5, 2026 |
| Mar 3, 2026 | NVCR NovoCure Ltd | AGrant or award Stock Option (Right to Buy)derivative | +58,488 | $0.00 | $0 | 66,006 | Mar 5, 2026 |
| Feb 27, 2026 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -1,555 | $13.66 | $21k | 76,751 | Mar 3, 2026 |
| Mar 2, 2026 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -408 | $13.49 | $5,505 | 76,343 | Mar 3, 2026 |
| Jan 11, 2026 | NVCR NovoCure Ltd | FTax withholding Ordinary Shares | -2,133 | $14.35 | $31k | 78,306 | Jan 12, 2026 |
| Nov 1, 2025 | NVCR NovoCure Ltd | FTax withholding Ordinary Shares | -168 | $12.81 | $2,152 | 83,388 | Nov 4, 2025 |
| Nov 4, 2025 | NVCR NovoCure Ltd | FTax withholding Ordinary Shares | -2,949 | $12.23 | $36k | 80,439 | Nov 4, 2025 |
| May 3, 2025 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -592 | $17.91 | $11k | 83,556 | May 5, 2025 |
| Nov 2, 2024 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -44 | $16.69 | $734 | 3,459 | Nov 6, 2024 |
| Nov 4, 2024 | NVCR NovoCure Ltd | AGrant or award Ordinary Shares | +30,138 | $0.00 | $0 | 33,597 | Nov 6, 2024 |
| Nov 4, 2024 | NVCR NovoCure Ltd | AGrant or award Stock Option (Right to Buy)derivative | +45,620 | $16.59 | $757k | 45,620 | Nov 6, 2024 |
| Nov 1, 2024 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -160 | $15.88 | $2,540 | 3,503 | Nov 4, 2024 |
Questions about Mukund Paravasthu
Answered from the filings on this page, as of the latest one.
Is Mukund Paravasthu buying or selling?
In the last 12 months Mukund Paravasthu reported 0 open-market buys worth $0 and 2 open-market sells worth $694k on SEC Form 4; the latest was sold $667k of NVCR on Mar 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Mukund Paravasthu's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mukund Paravasthu has 0.
Where does Mukund Paravasthu file Form 4?
Mukund Paravasthu has filed Form 4 at NVCR (NovoCure Ltd) as Chief Operating Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.